Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | SMO | Q99835 | 1/20 | 0.41 |
| ▸ | IDE | P14735 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 2/20 | 0.38 |
| ▸ | NOS2 | P35228 | 2/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | NOS3 | P29474 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL390651 | 0.85 | NOS1 (0.49) | HPGDSMN1; SMN2OPRD1KCNH2SMO | |
| SCHEMBL390540 | 0.84 | OPRD1 (0.57) | HPGDSMN1; SMN2OPRD1KCNH2SMO | |
| SCHEMBL390619 | 0.83 | HRH3 (0.56) | HPGDSMN1; SMN2OPRD1KCNH2SMO | |
| SCHEMBL390340 | 0.83 | HRH3 (0.54) | HPGDSMN1; SMN2OPRD1KCNH2SMO | |
| SCHEMBL10168032 | 0.82 | HSD17B10 (0.44) | HPGDSMN1; SMN2SMONPSR1 | |
| SCHEMBL388016 | 0.82 | HRH3 (0.57) | HPGDSMN1; SMN2KCNH2HRH3 | |
| SCHEMBL389756 | 0.81 | HRH3 (0.56) | HPGDSMN1; SMN2OPRD1KCNH2SMO | |
| SCHEMBL390338 | 0.81 | HRH3 (0.56) | HPGDSMN1; SMN2OPRD1KCNH2SMO | |
| SCHEMBL14340961 | 0.81 | MAPT (0.49) | HPGDSMN1; SMN2OPRD1KCNH2SMO | |
| SCHEMBL388764 | 0.81 | GRIN2D (0.49) | HPGDSMN1; SMN2OPRD1KCNH2SMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101618-B2 | 1,4-substituted piperazine derivatives | MSD K.K. (JP) | 2012-01-24 | — | — | US | disclosed |
| US-20090062293-A1 | 1,4-Substituted Piperazine Derivatives | MSD K.K. (JP) | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062293-A1 | 1,4-Substituted Piperazine Derivatives | GRIN1, GRM1, GRIN2C | HPGD 2246/4885SMN1; SMN2 960/4885OPRD1 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.